{"schema_version":"1","generated_at":"2026-11-05T01:58:26.080Z","data_as_of":null,"url":"https://www.findmykol.com/kol/mark-leick","json_url":"https://www.findmykol.com/kol/mark-leick/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"mark-leick","name":"Mark Leick","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Broad Institute","institution_url":"https://www.findmykol.com/institution/broad-institute","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1912325143","orcid":"0000-0003-3111-0221","openalex":"A5012987786"},"summary":"Mark Leick is an Oncology physician affiliated with Broad Institute. OpenAlex indexes 97 publications with 4,084 citations (h-index 26).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":97,"cited_by_count":4084,"h_index":26,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":2,"program_years":{"first":2021,"last":null},"rows_total":4,"shown":3,"withheld":1,"rows":[{"payer":"Adaptimmune","program_year":2025,"amount_usd":8500,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1912325143"},{"payer":"BioNTech SE","program_year":2025,"amount_usd":825,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1912325143"},{"payer":"BioNTech SE","program_year":2023,"amount_usd":825,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1912325143"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1912325143","source":"payments"},"prescribing":{"data_year":2019,"areas_total":1,"areas_shown":1,"areas":[{"area":"Anti-infectives","share_pct":100,"classes_total":1,"classes":[{"class":"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Famciclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2024,"last":2026},"rows_total":3,"shown":3,"withheld":0,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"K08CA289948","title":"Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinoma","fiscal_year":2026,"amount_usd":"297728","organization":"MASSACHUSETTS GENERAL HOSPITAL","source_url":"https://reporter.nih.gov/quickSearch/K08CA289948"},{"project":"K08CA289948","title":"Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinoma","fiscal_year":2025,"amount_usd":"297728","organization":"MASSACHUSETTS GENERAL HOSPITAL","source_url":"https://reporter.nih.gov/quickSearch/K08CA289948"},{"project":"K08CA289948","title":"Targeted delivery of a VEGF‐blocking scFv by CD70 CAR‐T cells to enhance anti‐tumor activity in renal cell carcinoma","fiscal_year":2024,"amount_usd":"297728","organization":"MASSACHUSETTS GENERAL HOSPITAL","source_url":"https://reporter.nih.gov/quickSearch/K08CA289948"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea","year":2026,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025032347","status":"verified"},{"title":"Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma","year":2026,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2025018137","status":"verified"},{"title":"In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma","year":2025,"journal":"Nature","source_url":"https://doi.org/10.1038/s41586-025-09489-8","status":"verified"},{"title":"Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2024028172","status":"verified"},{"title":"Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time","year":2025,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2025-012822","status":"verified"}],"source":"works"},"contact":{"address_1":"55 FRUIT ST","city":"Boston","state":"MA","zip":"021142621","phone":"520-861-8037","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1912325143","source":"identity"},"similar":[{"name":"Alan Mullen","slug":"alan-mullen","institution":"Broad Institute","specialty":"Gastroenterology","url":"https://www.findmykol.com/kol/alan-mullen","json_url":"https://www.findmykol.com/kol/alan-mullen/profile.json"},{"name":"Benjamin Ebert","slug":"benjamin-ebert","institution":"Broad Institute","specialty":"Hematology","url":"https://www.findmykol.com/kol/benjamin-ebert","json_url":"https://www.findmykol.com/kol/benjamin-ebert/profile.json"},{"name":"Susan Redline","slug":"susan-redline","institution":"Broad Institute","specialty":"Internal Medicine","url":"https://www.findmykol.com/kol/susan-redline","json_url":"https://www.findmykol.com/kol/susan-redline/profile.json"},{"name":"Patrick Ellinor","slug":"patrick-ellinor","institution":"Broad Institute","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/patrick-ellinor","json_url":"https://www.findmykol.com/kol/patrick-ellinor/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":1,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2026-01-22","provider_certified":"2026-01-22","collected_at":"2026-11-04T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2019},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}